Prostate Cancer's New Frontier: Quality of Life Challenges Surgical Norms

TORONTO, ON – July 24, 2026 – For decades, the primary objective in treating prostate cancer has been clear: eradicate the disease. But a growing body of evidence is forcing a critical re-evaluation of this singular focus, elevating a question that has long been secondary: at what cost to the patient’s quality of life? New data from a landmark clinical trial has thrown this question into sharp relief, presenting a direct challenge to the gold standard of robotic surgery and signaling a potential sea change in how we measure therapeutic success.

Profound Medical Corp. today announced results from its CAPTAIN trial, a head-to-head comparison between its incision-free TULSA Procedure™ and robotic radical prostatectomy (RP). The findings, presented at the Society of Robotic Surgery Annual Meeting, targeted a side effect rarely discussed openly but deeply felt by patients: penile shortening. The study found that one month after treatment, patients who underwent the TULSA Procedure experienced no median change in penile length. In stark contrast, those who received robotic surgery saw a median reduction of 0.65 cm. This seemingly small measurement carries immense weight, representing a new front in the battle for patient-centric cancer care.

Beyond Survival: A New Standard for Well-being

The business of medicine is ultimately the business of human outcomes. While oncologic control remains paramount, the definition of a successful outcome is expanding. The latest CAPTAIN trial data provides a powerful new metric in this evolution. Penile shortening, along with erectile dysfunction and incontinence, can have a devastating psychological impact, affecting a man's identity, self-esteem, and intimate relationships. Research has linked self-perceived penile shortening to lower quality of life and increased treatment regret.

“Because the penis may be deeply tied to their identity, masculinity, and/or self-worth, even small amounts of penile shrinkage can cause men a lot of additional worry and distress,” said Arun Menawat, Profound’s CEO and Chairman. “This new data points to the greater peace of mind that the TULSA Procedure can deliver to patients by gently, safely and precisely ablating prostate tissue while actively protecting surrounding structures.”

This is not an isolated finding. It builds upon previously released six-month data from the same trial, which demonstrated TULSA's statistically significant superiority over robotic RP in preserving both erectile function and urinary continence. In that analysis, 50% of TULSA patients preserved both functions, compared to just 24% in the robotic surgery arm. For leaders in healthcare organizations, this data is more than a clinical footnote; it’s a clear signal of shifting patient priorities and a potential realignment of value in cancer treatment. The ability to offer a therapy that demonstrably mitigates some of the most feared side effects of prostatectomy is a powerful differentiator.

The Clinical Evidence: Challenging a Surgical Juggernaut

The significance of the CAPTAIN trial lies not only in its results but in its design. As the first Level 1 randomized controlled trial to directly compare a novel technology against robotic RP for intermediate-risk prostate cancer, its findings carry substantial clinical weight. The trial, which enrolled 211 men across 23 sites, was designed to prove that the TULSA Procedure's cancer-fighting efficacy is no worse than surgery, while its safety and quality-of-life outcomes are superior.

The TULSA Procedure utilizes an MRI-guided, transurethral ultrasound device to ablate prostate tissue from the inside out, without any incisions. This real-time imaging allows surgeons to see, plan, and control the ablation, personalizing the treatment to the patient's specific anatomy and disease while actively protecting critical surrounding structures like the urinary sphincter and nerve bundles responsible for erectile function. This precision is the key to its favorable side-effect profile.

Beyond the headline functional outcomes, the trial also highlighted significant procedural and recovery advantages. TULSA patients experienced virtually no blood loss, had shorter hospital stays (typically discharged the same day), reported lower postoperative pain, and missed a median of nine fewer days of work compared to their counterparts undergoing robotic surgery. For hospital administrators and insurers, these metrics translate directly into bottom-line benefits: reduced resource utilization, lower risk of costly complications, and faster return to productivity for patients.

Reshaping a Multi-Billion Dollar Market

The findings present a formidable challenge to the status quo in the prostate cancer treatment market, a space projected to exceed $12 billion by the early 2030s. For nearly two decades, robotic-assisted surgery, dominated by Intuitive Surgical's da Vinci system, has been the ascendant force, used in the majority of prostatectomies in developed nations. Its rise was fueled by promises of a minimally invasive approach with better functional outcomes than traditional open surgery.

Now, Profound Medical is using the same playbook—leveraging superior patient-centric data—to disrupt the disruptor. By providing Level 1 evidence of superior functional outcomes on three of the most sensitive quality-of-life metrics, the company has forged a powerful competitive advantage. This is actionable intelligence for investors and healthcare executives who have watched the robotic surgery market mature. The CAPTAIN trial results suggest that a new wave of innovation focused on truly minimizing collateral damage is poised to capture market share.

The final piece of the puzzle for widespread adoption is reimbursement. With dedicated CPT codes for the TULSA procedure set to become effective in early 2025, the path to broader access and integration into clinical practice is becoming clearer. This development is expected to unlock a significant bottleneck, making the procedure a viable option for a much larger patient population and a more attractive investment for healthcare systems.

While the trial's primary three-year efficacy endpoint—measuring freedom from cancer progression—is still to come, the accumulated safety and quality-of-life data is already compelling. It forces a fundamental question for patients and their physicians: if two treatments offer similar chances of curing the cancer, but one offers a demonstrably better chance of preserving the life you want to live afterward, which one represents the superior value? For leaders looking to build resilient and innovative healthcare organizations, the answer to that question may illuminate the future of medical treatment itself.